EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Clinical trials for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) explained in plain language.
Never miss a new study
Get alerted when new EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) trials appear
Sign up with your email to follow new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for taming a rare and relapsing autoimmune disease
Disease control CompletedThis study tested whether a drug called rituximab is better than standard therapy at getting a rare inflammatory blood vessel disease (EGPA) into remission and keeping it there. It involved 107 adults with newly diagnosed or flaring EGPA, who were randomly assigned to receive eit…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Apr 02, 2026 05:56 UTC
-
Alcoholism drug repurposed to fight pain and fatigue in rare autoimmune diseases
Symptom relief CompletedThis study tested whether a very low dose of an existing drug, naltrexone, could improve daily life for people with vasculitis, a group of rare autoimmune diseases that cause blood vessel inflammation. Sixty patients whose disease was stable but who still struggled with poor phys…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Mar 30, 2026 14:33 UTC